Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The study population strictly includes diagnostically confirmed TNBC patients only. For the benign tissue, TNBC patients with benign tumors are the study population. For the control, healthy breast tissue adjacent to the tumor can be resected from the same patient or as per the convenience of the clinicians. For the lymph node tissue, TNBC patients with sentinel or axillary LN +ve patients are included. For the lymph node tissue control, axillary LN-ve tissue can be included.
Exclusion criteria
Exclusion criteria: The study population strictly includes diagnostically confirmed TNBC patients only. For the benign tissue, TNBC patients with benign tumors are the study population. For the control, healthy breast tissue adjacent to the tumor can be resected from the same patient or as per the convenience of the clinicians. For the lymph node tissue, TNBC patients with sentinel or axillary LN +ve patients are included. For the lymph node tissue control, axillary LN-ve tissue can be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A Biomarker that indicates the specific drug target might be used to select patients for a trial where PFS is the primary endpoint. If the biomarker is present, that means the treatment is most likely to be effective, and PFS might be longer.Timepoint: Samples from the past 5 years will be studied. | — |
Secondary
| Measure | Time frame |
|---|---|
| completely performed invitro with the cell lines. Only microbes will be isolated from the human tissue sample, and after isolation, the progression of breast cancer cell lines in the presence of tumor microbes will be performed through several in vitro assays. So, there is no requirement for any endpoints.Timepoint: Samples from the past 5 years will be studied. | — |
Countries
India
Contacts
IIT Roorkee, Uttarakhand